371 related articles for article (PubMed ID: 34628053)
1. Editing outside the body: Ex vivo gene-modification for β-hemoglobinopathy cellular therapy.
Rosanwo TO; Bauer DE
Mol Ther; 2021 Nov; 29(11):3163-3178. PubMed ID: 34628053
[TBL] [Abstract][Full Text] [Related]
2. A New Era for Hemoglobinopathies: More Than One Curative Option.
Psatha N; Papayanni PG; Yannaki E
Curr Gene Ther; 2017; 17(5):364-378. PubMed ID: 29357790
[TBL] [Abstract][Full Text] [Related]
3. Gene Therapy for β-Hemoglobinopathies.
Cavazzana M; Antoniani C; Miccio A
Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
[TBL] [Abstract][Full Text] [Related]
4. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
6. Genome Editing for the β-Hemoglobinopathies.
Porteus MH
Adv Exp Med Biol; 2017; 1013():203-217. PubMed ID: 29127682
[TBL] [Abstract][Full Text] [Related]
7. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy for Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease.
Leonard A; Tisdale JF; Bonner M
Hematol Oncol Clin North Am; 2022 Aug; 36(4):769-795. PubMed ID: 35773052
[TBL] [Abstract][Full Text] [Related]
9. Gene Therapy for β-Hemoglobinopathies: From Discovery to Clinical Trials.
Segura EER; Ayoub PG; Hart KL; Kohn DB
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992422
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.
Germino-Watnick P; Hinds M; Le A; Chu R; Liu X; Uchida N
Cells; 2022 Jun; 11(11):. PubMed ID: 35681538
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
12. Gene Therapy Approaches to Hemoglobinopathies.
Ferrari G; Cavazzana M; Mavilio F
Hematol Oncol Clin North Am; 2017 Oct; 31(5):835-852. PubMed ID: 28895851
[TBL] [Abstract][Full Text] [Related]
13. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem Cells for Gene Therapy of Beta-Thalassemia and Sickle Cell Disease.
Cai L; Bai H; Mahairaki V; Gao Y; He C; Wen Y; Jin YC; Wang Y; Pan RL; Qasba A; Ye Z; Cheng L
Stem Cells Transl Med; 2018 Jan; 7(1):87-97. PubMed ID: 29164808
[TBL] [Abstract][Full Text] [Related]
14. Genome-based therapeutic interventions for β-type hemoglobinopathies.
Karamperis K; Tsoumpeli MT; Kounelis F; Koromina M; Mitropoulou C; Moutinho C; Patrinos GP
Hum Genomics; 2021 Jun; 15(1):32. PubMed ID: 34090531
[TBL] [Abstract][Full Text] [Related]
15. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
16. In vivo base editing by a single i.v. vector injection for treatment of hemoglobinopathies.
Li C; Georgakopoulou A; Newby GA; Everette KA; Nizamis E; Paschoudi K; Vlachaki E; Gil S; Anderson AK; Koob T; Huang L; Wang H; Kiem HP; Liu DR; Yannaki E; Lieber A
JCI Insight; 2022 Oct; 7(19):. PubMed ID: 36006707
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
Sii-Felice K; Giorgi M; Leboulch P; Payen E
Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for hemoglobinopathies: the state of the field and the future.
Chandrakasan S; Malik P
Hematol Oncol Clin North Am; 2014 Apr; 28(2):199-216. PubMed ID: 24589262
[TBL] [Abstract][Full Text] [Related]
19. Genome editing approaches to β-hemoglobinopathies.
Brusson M; Miccio A
Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells.
Dever DP; Bak RO; Reinisch A; Camarena J; Washington G; Nicolas CE; Pavel-Dinu M; Saxena N; Wilkens AB; Mantri S; Uchida N; Hendel A; Narla A; Majeti R; Weinberg KI; Porteus MH
Nature; 2016 Nov; 539(7629):384-389. PubMed ID: 27820943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
